Pacira BioSciences, Inc. (PCRX) - It Appears that the FDA has Approved eVenus' Generic Product.

July 5, 2024

Yesterday (July 1, 2024) in after-market hours, it appears that the FDA has now approved eVenus' Generic Exparel.

We currently believe that this news may be Negative for the share-price of Pacira BioSciences, Inc. (PCRX).

Please see the following link for more details:

Drugs@FDA: FDA-Approved Drugs

Sincerely,

Justin Wilcox, Senior Research Analyst

MDC Financial Research, LLC

Mobile: (415) 515-9063

Justin@MDCFinancial.com

Disclosure: Nobody at MDC Financial Research, LLC currently has any positions in Pacira BioSciences, Inc. (PCRX).

-------------------------

Copyright © 2024, MDC Financial Research, LLC (“MDC”). This e-mail is only for the use of paid subscribers to MDC’s “Event-Driven Legal℠” investment-research service, and you should not disseminate, distribute, and/or alter this e-mail. If you are not authorized to receive this e-mail, please notify the sender immediately and delete this e-mail from your system. There may be errors and/or omissions in this e-mail. Any opinion(s) expressed in this e-mail reflects MDC’s judgment as of the timestamp on this e-mail. We are not attorneys, and this email does not constitute legal advice. To manage your subscription, please call: (510) 894-4476.

-------------------------

We are not lawyers, and we do not practice law or render legal advice. MDC Financial Research is a State-Registered Investment Advisor with Financial Analysts that approach legal situations from an investor angle for investment purposes. MDC Financial Research, LLC is currently registered as an Investment Advisor in the States of California, Illinois, and New York. Additional information and disclosures are contained in MDC Financial Research’s Form ADV and Form ADV Part 2 (Brochure).

Contact

MDC Financial Research, LLC
El Dorado Hills, CA
(510) 894-4476
Info@MDCFinancial.com